包装 | 价格(元) |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
生物活性 | Cotadutide (MEDI0382) acetate is a potent dual agonist ofglucagon-like peptide-1 (GLP-1)andGCGRwithEC50values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D)[1][2][3]. | ||||||||||||||||
IC50& Target | EC50: 6.9 pM (GLP-1); 10.2 pM (GCGR)[1] | ||||||||||||||||
体外研究 (In Vitro) | Cotadutide acetate stimulates a concentration-dependent increase in cAMP accumulation in rat (INS-1 832/3) and human (EndoC-βH1) β-cell lines (EC50: 226 pM and 1051 pM, respectively ), as well as rat, mouse and human hepatocytes (EC50: 462 pM, 840 pM, 1447 pM, respectively)[1].Cotadutide (100 pM-1 μM) acetate potentiates glucose-stimulated insulin secretion in the rat (INS-1 832/3) pancreatic β‐cell line and increases glucose output in rat hepatocytes[1].Cotadutide (100 nM, 2 h) acetate induces mitochondrial turnover and enhances mitochondrial function in mouse primary hepatocytes[2]. | ||||||||||||||||
体内研究 (In Vivo) | Cotadutide (10 nmol/kg, s.c., once) acetate suppresses food intake in DIO mice relative to vehicle‐ reated controls[1].Cotadutide (10 or 30 nmol/kg, s.c., once daily for 14-16 weeks) acetate reduces body weight in DIO mice[1].Cotadutide (30 nmol/kg, s.c., once a day for 6 weeks) acetate reduces hepatic fibrosis and inflammation in in ob/ob AMLN NASH mice[2].
| ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 3788.14 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C169H256N42O57 | ||||||||||||||||
Sequence | 1'-{palmtoyl-Glu}; His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Lys-Ser-Glu-Tyr-Leu-Asp-Ser-Glu-Arg-Ala-Arg-Asp-Phe-Val-Ala-Trp-Leu-Glu-Ala-Gly-Gly (Amide bridge: Glu1'-Lys10) | ||||||||||||||||
Sequence Shortening | 1'-{palmtoyl-Glu}; HSQGTFTSDKSEYLDSERARDFVAWLEAGG (Amide bridge: Glu1'-Lys10) | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 | Sealed storage, away from moisture
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) | ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 12.5 mg/mL(3.30 mM;Need ultrasonic) H2O : 2 mg/mL(0.53 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|